Translational neuroscience

Labroots Hosts 12th Annual Neuroscience Online Event Scheduled on March 6, 2024

Retrieved on: 
Thursday, February 29, 2024
SVKM's NMIMS, Pennsylvania State University, Artificial intelligence, DSM-IV codes, University, Kellogg School, Behavior, Diagnosis, Health, Labroots, Associate, Gubra, Panel discussion, Bangladesh Technical Education Board, Networking hardware, Blood test, Translation, Ethics, NIH, Computer, Data collection, Aarhus University, Associate professor, Initiative, BRAIN, Dementia, Brain, Parkinson's disease, Natural language processing, University of Pennsylvania, Language, Drug discovery, BRAIN Initiative, Neurodegenerative disease, Thought, Social behavior, Heart, Translational neuroscience, Lewy body, Research, Multiple, Neural engineering, Collection, MD, Discovery, Depression, Medical imaging

YORBA LINDA, Calif., Feb. 29, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its free 12th annual event in the Neuroscience Virtual Event Series to be held on March 6, 2024. Marking a decade of sharing ground breaking research and scientific discovery via Labroots' immersive platform, this dynamic event continues its tradition of showcasing some of the brightest minds at the forefront of neuroscience impacting health and disease today.

Key Points: 
  • I am excited to discuss this at Labroots' 12th annual event in the Neuroscience Virtual Event Series."
  • Hosted by Labroots and produced on Chati, participants in the event can connect seamlessly across desktop and mobile devices while engaged in a one-stop educational experience.
  • Remember to use the hashtag #LRneuro to follow the conversation and connect with other members of the global Neuroscience community!
  • Follow @Neuroscience_LR on Twitter and @Neuroscience.LR on Facebook to stay up to date with the latest Trending News in Neuroscience.

SYNAPS Dx Announces Prestigious Scientific Advisory Board to Guide Strategy and Commercialization of DISCERN™, Only Autopsy-Validated Test for Accurate Diagnosis of Alzheimer's Disease

Retrieved on: 
Wednesday, January 17, 2024
Research, Managed Care, Pharmaceutical, Mental Health, Medical Devices, Genetics, Science, Biotechnology, Neurology, Medical Supplies, Practice Management, Health, DISCERN, Patient, Dementia, Biology, ELISA, Multimedia, Culture, UTMB, Knowledge, Diagnosis, Neuron, Translational neuroscience, Memory, Software-defined, Neurodegenerative disease, Immunotherapy, Fibroblast, Skin, USC, Protein kinase C, SAB, Disease, Michigan State University, FDA, Therapy, Doctor of Philosophy, Inflammation, Master of Science, Brain, Ageing, Physician, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240117576710/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240117576710/en/
    • Alberto J. Espay, MD, MSc, chairman of the SAB, has over 300 published peer-reviewed research articles and 10 books on neurodegenerative diseases.
  • • Giulio Taglialatela, PhD, serves as the vice chair for research of the Department of Neurology and the director of the UTMB Mitchell Center for Neurodegenerative Diseases.
  • “We are honored to partner with such exceptional thought leaders who are shaping the future of brain health and advancing the biology of memory.
  • The AD-biomarker index also composes one of the three assays and tests skin fibroblasts from biopsies to culture to confluency.

Metabolon and Sheffield Institute for Translational Neuroscience Join Forces to Propel ALS Research and Biomarker Discovery

Retrieved on: 
Tuesday, January 23, 2024
Patient, MNDA, Research, MND, Partnership, Metabolomics, CSF, Translational neuroscience, University, Brain cell, Medicine, Motor neuron diseases, Cell, Plasma, Disease, Facial muscles, Fluid mechanics, Biomarker, Neurology, Nervous system, Metabolism, Diagnosis, Motor Neurone Disease Association, Pharmaceutical industry

MORRISVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a strategic partnership with the Sheffield Institute for Translational Neuroscience (SITraN) and A Multicentre Biomarker Resource Strategy in ALS (AMBRoSIA). The collaboration aims to explore novel pathogenic mechanisms of ALS that may expand therapeutic possibilities to a patient population in need of additional treatment options.

Key Points: 
  • Motor neuron diseases (MND), which include ALS, are progressive disorders that affect voluntary muscle control.
  • Currently, there is no cure for these diseases, and approximately 80% of people with ALS die within two to five years of diagnosis.
  • "Metabolon is thrilled to collaborate with SITraN, a leading institution in translational neuroscience, and AMBRoSIA.
  • Together, we aim to drive significant progress in ALS research and biomarker discovery, bringing us closer to effective diagnostic and therapeutic solutions for this challenging disease," said Karl Bradshaw, Chief Business Officer at Metabolon.

Metabolon and Sheffield Institute for Translational Neuroscience Join Forces to Propel ALS Research and Biomarker Discovery

Retrieved on: 
Tuesday, January 23, 2024
Patient, MNDA, Research, MND, Partnership, Metabolomics, CSF, Translational neuroscience, University, Brain cell, Medicine, Motor neuron diseases, Cell, Plasma, Disease, Facial muscles, Fluid mechanics, Biomarker, Neurology, Nervous system, Metabolism, Diagnosis, Motor Neurone Disease Association, Pharmaceutical industry

MORRISVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a strategic partnership with the Sheffield Institute for Translational Neuroscience (SITraN) and A Multicentre Biomarker Resource Strategy in ALS (AMBRoSIA). The collaboration aims to explore novel pathogenic mechanisms of ALS that may expand therapeutic possibilities to a patient population in need of additional treatment options.

Key Points: 
  • Motor neuron diseases (MND), which include ALS, are progressive disorders that affect voluntary muscle control.
  • Currently, there is no cure for these diseases, and approximately 80% of people with ALS die within two to five years of diagnosis.
  • "Metabolon is thrilled to collaborate with SITraN, a leading institution in translational neuroscience, and AMBRoSIA.
  • Together, we aim to drive significant progress in ALS research and biomarker discovery, bringing us closer to effective diagnostic and therapeutic solutions for this challenging disease," said Karl Bradshaw, Chief Business Officer at Metabolon.

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, November 14, 2023
Acumen, Neurogranin, Research, Safety, Food, AAIC, Incidence, ALS, Immunoglobulin G, Translational neuroscience, PROMIS, CSF, Patient, MSA, Pharmacokinetics, ITN, Immunization, Therapy, Blood, Neuroscience, ARIA, PMN, Biomarker, Cerebrospinal fluid, Multiple system atrophy, Initiative, Lecanemab, Pharmaceutical industry, Cryptocurrency, Boston

CAMBRIDGE, Massachusetts, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • “The third quarter was marked by significant progress across both our clinical and corporate initiatives,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences.
  • These results replicated biomarker findings from the CLARITY-AD trial of lecanemab, which also predominantly targets soluble amyloid beta oligomers.
  • In July 2023, the Company presented preclinical data from mouse vaccination studies at AAIC 2023.
  • Net loss was $2.4 million for the quarter ended September 30, 2023, compared to a net loss of $6.0 million for the same period in 2022.

6th Annual Neuroscience R&D Conference, London, United Kingdom - October 9-10, 2023

Retrieved on: 
Thursday, September 21, 2023
Interactivity, University, Therapy, Senior, Blood–brain barrier, Proteomics, CNS, Assistant, University of Nottingham, Patient, Access, University of Sheffield, Drug discovery, Neurology, AI, Conference, Alzheimer's disease, University of Oxford, Medical device, Pharmaceutical industry, Neuroscience, Translational neuroscience

DUBLIN, Sept. 21, 2023 /PRNewswire/ -- The "Neuroscience R&D Conference" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 21, 2023 /PRNewswire/ -- The "Neuroscience R&D Conference" conference has been added to ResearchAndMarkets.com's offering.
  • With the advent of neural implants and novel therapies, the cure of multiple neurodegenerative disorders proves wholesome for the patients' suffering.
  • The increasing in severity of neurodegenerative diseases, demands the discovery of new translational approaches in neuroscience research.
  • Case studies presented from leading technology collaborations, Interactive panels, and breakout sessions along with Access to online presentations on-demand post-summit.

Long-time Collaborators Botond Roska and José-Alain Sahel Win International Prize for Translational Neuroscience

Retrieved on: 
Thursday, June 22, 2023
Molecular biology, Faculty, IOB, Human, Natural science, University, Doctor of Philosophy, Optogenetics, Max Planck Society, Eye, Light, Coronavirus Scientific Advisory Board, Brain, Retina, COVID, University of Pittsburgh School of Medicine, Cell, DSM-IV codes, Science, MD, University of Toronto Faculty of Medicine, Patient, Louis Pasteur University, Neuroscience, Botond Roska, Translational neuroscience, Gene, Distinguishing, Wilfrid Sellars, International Prize (Fyssen Foundation), Sahel, Pharmaceutical industry, Nature Medicine, Medicine, Ophthalmology

The two scientists met in 2001 while Roska was studying for a Ph.D. in cell and molecular biology in Berkeley, US. He had come to Strasbourg, France, to spend a month at Louis Pasteur University, where Sahel was then a laboratory director. Late one night, Roska succeeded in recording the activity of some retinal cells, and his boisterous reaction prompted Sahel --who was upstairs and still working-- to investigate the commotion. “Suddenly, Dr. Sahel was there at the door, asking ‘What is going on here?’” Roska says. “So, I showed him my recordings, and we spent hours discussing the research.”

Key Points: 
  • The €60,000 annual prize rewards biomedical scientists and clinicians who make exceptional contributions toward the understanding of neurobiology and neurological diseases.
  • The two scientists met in 2001 while Roska was studying for a Ph.D. in cell and molecular biology in Berkeley, US.
  • “Suddenly, Dr. Sahel was there at the door, asking ‘What is going on here?’” Roska says.
  • Roska and I share a common enthusiasm and keen interest in science, and our collaboration continually produces new ideas.

The University of Oxford and Selvita Collaborate to Advance Potential Therapeutics for Parkinson's Disease

Retrieved on: 
Monday, June 5, 2023
Neuron, Posture, University, Genetics, WSE, Neurodegenerative disease, Sleep, Pathology, University of Oxford, Dopamine, Cell, Movement, DSM-IV codes, Neuroscience, Parkinson's disease, Patient, Alpha-synuclein, Drug discovery, Neurology, Translational neuroscience, Movement disorder, Death, Team, Disease, Pharmaceutical industry

While Parkinson's disease is the second most common neurodegenerative disease affecting ~7 million people worldwide, there are only symptomatic therapies available.

Key Points: 
  • While Parkinson's disease is the second most common neurodegenerative disease affecting ~7 million people worldwide, there are only symptomatic therapies available.
  • At the molecular level, it is caused by the build-up of a small protein called alpha-synuclein which forms aggregates inside vulnerable neurons.
  • The inability of cells to efficiently clear these aggregates may lead to the death of neurons and the emergence of characteristic symptoms of the disease.
  • Professor George Tofaris and his Team at the University of Oxford have identified key protein disposal factors that affect alpha-synuclein aggregation, and could be important drug targets for disease modification.

BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies

Retrieved on: 
Monday, June 5, 2023
Research, Technology, Neurology, Clinical Trials, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Central nervous system, University, Neurodegenerative disease, C9orf72, CNS, BAI, Oxidative stress, Euronext, Senior lecturer, Patient, Translational neuroscience, Sheffield Institute of Arts Gallery, ALS, IND, Pharmaceutical industry

BenevolentAI ​​(Euronext Amsterdam: BAI), a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712.

Key Points: 
  • BenevolentAI ​​(Euronext Amsterdam: BAI), a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712.
  • BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies.
  • Impaired retinoic acid signalling has been shown to result in neuroinflammation, oxidative stress and mitochondrial dysfunction, all hallmarks of ALS.
  • Anne Phelan, Chief Scientific Officer, BenevolentAI, said: “There remains a significant and urgent need for new and alternative therapies for patients with ALS.

Parkinson's Foundation Receives Grant to Fund Critical Research, Genetic Testing and Counseling

Retrieved on: 
Tuesday, March 7, 2023
Encephalitis, Meyers, Parkinson's disease, Barrow Neurological Institute, Candid (organization), Genetics, Research, ACMSD, Pat Simon, DRS, Senior counsel, PD, Hope, Genetic testing, Parkinson's Foundation, Doctor of Philosophy, Translational neuroscience, Pharmaceutical industry, Palladium, Barrow

NEW YORK and MIAMI, March 7, 2023 /PRNewswire/ -- The Parkinson's Foundation has received a grant of nearly $800,000 from the Pat Simone Charitable Foundation, Inc. to fund research at Barrow Neurological Institute, which includes the Muhammad Ali Parkinson Center, a Parkinson's Foundation Center of Excellence. The grant aims to improve the lives of people with Parkinson's disease (PD) in Arizona by funding promising scientists conducting innovative research and increasing local participation in PD GENEration: Mapping the Future of Parkinson's Disease.

Key Points: 
  • The work at Barrow has the potential to improve the lives of the local PD community—an estimated 18,000 people who live with PD in Arizona.
  • Dr. Meyers received a prestigious Parkinson's Foundation Postdoctoral Fellowship for Basic Scientists in support of this study.
  • Additionally, funding will expand local participation in PD GENEration, offering genetic testing and counseling (in English and Spanish) at no cost for people with PD in Arizona.
  • Genetic testing can help people with PD and their clinicians identify whether they may qualify for enrollment in certain clinical trials.